XML 99 R85.htm IDEA: XBRL DOCUMENT v3.25.3

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Thousands						1 Months Ended		12 Months Ended
	Dec. 08, 2025	Dec. 02, 2025	Nov. 05, 2025	Sep. 26, 2025	Mar. 18, 2025	Jan. 02, 2026	Sep. 30, 2024	Dec. 31, 2026	Sep. 30, 2025	Jun. 16, 2025	Jun. 15, 2025	Jun. 13, 2025	Jun. 12, 2025	Feb. 14, 2025	Dec. 31, 2024
Subsequent Event [Line Items]
Common stock, par value (in dollars per share)									$ 0.001	$ 0.001	$ 0.001	$ 0.001			$ 0.001
Pre-Funded Warrant
Subsequent Event [Line Items]
Estimated purchase price (in dollars per share)													$ 13.22
Estimated purchase price warrants (in dollars per share)												$ 1.000	$ 1.9109	$ 1.9109
Subsequent Event | Private Placement
Subsequent Event [Line Items]
Number of shares issued and sold (in shares)	13,795,685
Common stock, par value (in dollars per share)	$ 0.001
Estimated purchase price (in dollars per share)	$ 13.41
Consideration received	$ 185,000
Maximum percentage ownership after exercise, upon 61 days notice	19.99%
Notice period	61 days
Subsequent Event | Private Placement | Pre-Funded Warrant
Subsequent Event [Line Items]
Estimated purchase price (in dollars per share)	$ 13.409
Estimated purchase price warrants (in dollars per share)	$ 0.001
Maximum percentage ownership after exercise	9.99%
Kelun-Biotech | CR-001 | License Agreement Terms | Subsequent Event
Subsequent Event [Line Items]
Consideration transferred, period		30 days
Development milestone payment		$ 30,000
Kelun-Biotech | CR-001 | License Agreement Terms | Subsequent Event | Forecast
Subsequent Event [Line Items]
Consideration transferred						$ 20,000
Combination study approval payment								$ 5,000
Kelun-Biotech | SKB105 | License Agreement Terms | Subsequent Event
Subsequent Event [Line Items]
Consideration transferred, period		30 days
Development milestone payment		$ 345,000
Sale based milestone payment		$ 902,500
Mid-single digits to low-double digits royalty payment, period		18 months
Low-single digits to low-double digits royalty payment, period		24 months
Kelun-Biotech | SKB105 | License Agreement Terms | Subsequent Event | Forecast
Subsequent Event [Line Items]
Consideration transferred						$ 80,000
Paragon Option Agreements | Paragon Therapeutics | CR-002 | License Agreement Terms
Subsequent Event [Line Items]
Non-refundable milestone payments				$ 46,000			$ 46,000
Paragon Option Agreements | Paragon Therapeutics | CR-002 | License Agreement Terms | Subsequent Event
Subsequent Event [Line Items]
Non-refundable milestone payments			$ 46,000
Paragon Option Agreements | Paragon Therapeutics | CR-001 | License Agreement Terms
Subsequent Event [Line Items]
Non-refundable milestone payments					$ 22,000		$ 22,000

X

- Definition

Asset Acquisition, Combination Study Approval Payment

+ References

No definition available.

+ Details

Name:	cbio_AssetAcquisitionCombinationStudyApprovalPayment
Namespace Prefix:	cbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Asset Acquisition, Consideration Transferred, Period

+ References

No definition available.

+ Details

Name:	cbio_AssetAcquisitionConsiderationTransferredPeriod
Namespace Prefix:	cbio_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Asset Acquisition, Development Milestone Payments, Maximum

+ References

No definition available.

+ Details

Name:	cbio_AssetAcquisitionDevelopmentMilestonePaymentsMaximum
Namespace Prefix:	cbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Asset Acquisition, Maximum Aggregate Milestone Payments

+ References

No definition available.

+ Details

Name:	cbio_AssetAcquisitionMaximumAggregateMilestonePayments
Namespace Prefix:	cbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Asset Acquisition, Sale Based Milestone Payment, Low-Single Digits To Low-Double Digits Royalty Payment, Period

+ References

No definition available.

+ Details

Name:	cbio_AssetAcquisitionSaleBasedMilestonePaymentLowSingleDigitsToLowDoubleDigitsRoyaltyPaymentPeriod
Namespace Prefix:	cbio_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Asset Acquisition, Sale Based Milestone Payment, Mid-Single Digits To Low-Double Digits Royalty Payment, Period

+ References

No definition available.

+ Details

Name:	cbio_AssetAcquisitionSaleBasedMilestonePaymentMidSingleDigitsToLowDoubleDigitsRoyaltyPaymentPeriod
Namespace Prefix:	cbio_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Asset Acquisition, Sales-Based Milestone Payments, Maximum

+ References

No definition available.

+ Details

Name:	cbio_AssetAcquisitionSalesBasedMilestonePaymentsMaximum
Namespace Prefix:	cbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Class Of Warrant Or Right, Exercisable Condition, Maximum Percentage Ownership After Exercise

+ References

No definition available.

+ Details

Name:	cbio_ClassOfWarrantOrRightExercisableConditionMaximumPercentageOwnershipAfterExercise
Namespace Prefix:	cbio_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Class Of Warrant Or Right, Exercisable Condition, Maximum Percentage Ownership After Exercise, Upon 61 Days Notice

+ References

No definition available.

+ Details

Name:	cbio_ClassOfWarrantOrRightExercisableConditionMaximumPercentageOwnershipAfterExerciseUpon61DaysNotice
Namespace Prefix:	cbio_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Sale Of Stock, Percentage Of Ownership After Transaction, Notice Period

+ References

No definition available.

+ Details

Name:	cbio_SaleOfStockPercentageOfOwnershipAfterTransactionNoticePeriod
Namespace Prefix:	cbio_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 55
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479908/805-50-55-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480060/805-50-25-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-2

+ Details

Name:	us-gaap_AssetAcquisitionConsiderationTransferred
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

+ Details

Name:	us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Cash received on stock transaction after deduction of issuance costs.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockPricePerShare
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481674/830-30-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483399/855-10-50-2

+ Details

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=cbio_PreFundedWarrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=cbio_KelunBiotechMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cbio_CR001Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cbio_SKB105Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	cbio_LicenseAgreementAxis=cbio_ParagonOptionAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=cbio_ParagonTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=cbio_CR002Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: